Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S (NASDAQ: EVAX) is a clinical-stage TechBio company that regularly issues news on its AI-Immunology™ powered vaccine and immunotherapy programs. The company’s updates highlight progress across cancer, infectious disease and autoimmune disease research, making EVAX news relevant for investors and followers of AI-driven biotechnology.
News from Evaxion often covers clinical and preclinical data from its oncology pipeline, including the personalized cancer vaccine EVX-01 for advanced melanoma and the ERV-based off-the-shelf cancer vaccine candidate EVX-04 for acute myeloid leukemia. Releases may detail biomarker findings, immune response data, and presentations at major scientific meetings such as oncology and hematology conferences.
On the infectious disease side, Evaxion publishes updates on vaccine candidates like the gonorrhea program EVX-B2 and the CMV vaccine program EVX-V1. These announcements can include preclinical efficacy data, discovery of novel AI-identified antigens, and progress in optimizing vaccine components such as AI-optimized glycoprotein antigens. Business development news may also describe option decisions, out-licensing arrangements and partnership discussions with pharmaceutical companies.
Corporate and financial communications form another important part of the EVAX news flow. Evaxion reports business updates, financial results, capital raises, changes to its Articles of Association related to share capital, and its financial calendar through press releases and accompanying SEC Form 6-K filings. The company also issues announcements about strategic milestones, such as expanding AI-Immunology™ into autoimmune diseases or enhancing the platform with automated vaccine design modules.
This news page aggregates these items so readers can follow Evaxion’s scientific progress, platform evolution, partnership activity and corporate developments in one place. For those tracking AI-based drug discovery, cancer vaccines and infectious disease vaccines, the EVAX news feed provides ongoing insight into how Evaxion applies its AI-Immunology™ platform across multiple therapeutic areas.
Evaxion (NASDAQ: EVAX) will provide a business update and report its full year 2025 financial results on March 5, 2026 before Nasdaq opening. Executive Management will host a conference call and webcast at 14:30 CET / 08:30 EST.
Registration is required to join the call for dial-in numbers and PIN; the webcast will be accessible live and a recording will be posted on the company website shortly after the event.
Evaxion (NASDAQ: EVAX) is expanding its proprietary AI-Immunology™ platform to include autoimmune diseases, adding a third core disease area alongside cancer and infectious disease.
The company plans to expand and train the platform for autoimmune applications in the second half of 2026. Evaxion says this work is included in its cashflow outlook and does not change cash runway, which extends into the second half of 2027. The move aims to increase program quantity and partnership potential.
Key 2026 milestones target H1 and H2 events, including additional EVX-01 biomarker data, EVX-01 three-year phase 2 efficacy data (H2), a regulatory filing for EVX-04 phase 1 (H2), and EVX-B4 antigen design and preclinical validation (H2).
Evaxion (NASDAQ: EVAX) will present its 2026 company milestones at the Biotech Showcase in San Francisco on January 13, 2026.
CEO Helen Tayton-Martin will deliver the company update on Tuesday, January 13, 2026 at 2:00 PM PST / 11:00 PM CET on Track: Yosemite C (Ballroom Level). The Biotech Showcase runs January 12-14, 2026 and coincides with the J.P. Morgan Healthcare Conference; Evaxion plans stakeholder meetings and investor engagement throughout the week.
Contact: Mads Kronborg, Vice President Investor Relations & Communication, +45 53 54 82 96, mak@evaxion.ai.
Evaxion (NASDAQ: EVAX) announced on December 19, 2025 that MSD will not exercise its option to develop the protein-based version of Evaxion’s Gonorrhea vaccine candidate EVX-B2, allowing Evaxion to retain global rights and seek a new licensing partner.
Evaxion noted preclinical studies show EVX-B2 protects against Gonorrhea and that MSD earlier exercised an option on a separate candidate, EVX-B3, for which Evaxion is eligible for up to $592 million in milestones plus royalties. Evaxion said the MSD decision does not affect its cash runway, which extends to the second half of 2027. Evaxion is also developing an mRNA version of EVX-B2 with Afrigen Biologics.
Evaxion (NASDAQ: EVAX) presented new preclinical data for its AML vaccine candidate EVX-04 at the ASH Annual Meeting on December 6, 2025. Using the company's AI-Immunology™ platform and AML patient sequencing data, EVX-04 comprises 16 ERV antigen fragments selected from ~5 million fragments for cross-patient relevance and immunogenic potential.
In preclinical tumor models, EVX-04 induced strong, specific T-cell responses and prevented tumor growth. The program is positioned as an off-the-shelf therapeutic vaccine intended for immediate administration after diagnosis and described as broadly applicable to other cancers where conserved immunogenic ERV antigens are found.
Evaxion (NASDAQ: EVAX) announced new preclinical data for its multi-component cytomegalovirus vaccine program EVX-V1 on November 20, 2025. Using its AI-Immunology™ platform, the company identified novel CMV antigens that induce specific immune responses, inhibit viral infection and reduce cell-to-cell spread in cellular and animal models. Evaxion also reports an AI-optimized pre-fusion glycoprotein B (gB) antigen with enhanced CMV neutralization versus a traditional gB antigen. Evaxion is continuing preclinical optimization and is exploring strategic partnerships to support non-clinical and clinical advancement.
Evaxion (NASDAQ: EVAX) announced its 2026 financial calendar on November 12, 2025. Key scheduled dates include:
- March 5, 2026 – Business update and full year 2025 financial results
- April 16, 2026 – Annual General Meeting
- May 7, 2026 – Business update and Q1 2026 financial results
- August 20, 2026 – Business update and Q2 2026 financial results
- November 19, 2026 – Business update and Q3 2026 financial results
The company said the full calendar is available on its website and provided investor relations contact details.
Evaxion (NASDAQ: EVAX) presented new biomarker and immune data for its AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting on November 7, 2025.
Data from the phase 2 trial—conducted in combination with Merck's anti-PD-1 therapy KEYTRUDA—report longitudinal blood sampling that characterized circulating T-cell subsets before, during and after treatment. In analyzed patient subsets, clinical responses were accompanied by a rapid and sustained induction of EVX-01-specific T cells. The release complements previously presented two-year clinical efficacy data from the same trial.
Evaxion (NASDAQ: EVAX) reported Q3 2025 results and a business update on November 6, 2025. Key clinical and corporate highlights include appointment of Dr Helen Tayton-Martin as CEO effective Nov 24, 2025, presentation of two‑year phase 2 data for personalized cancer vaccine EVX‑01 showing a 75% ORR (12/16) with four complete responses and 92% still responding at two years, and out‑licensing of bacterial vaccine EVX‑B3 to MSD with a $7.5M option fee and potential future payments up to $592M. Financially, Q3 revenue was $7.5M, net income $4.6M, cash of $10.6M as of Sep 30, 2025, and cash runway extended to the second half of 2027.
Evaxion (NASDAQ: EVAX) announced EVX-04, an AI-designed precision therapeutic cancer vaccine candidate for acute myeloid leukemia (AML) developed using its AI‑Immunology™ platform. EVX-04 targets multiple non-conventional ERV tumor antigens from the dark genome that are present in tumors but absent in normal tissue and is designed as an off‑the‑shelf vaccine for immediate use after diagnosis. New preclinical data showing strong T‑cell responses and cancer cell killing will be presented orally at the American Society of Hematology (ASH) Annual Meeting on December 6, 2025.
Presentation: Abstract #278, Emerging Tools session, Hyatt Regency Ballroom, 2:00pm ET; presenter Rasmus Villebro.